Teacher Retirement System of Texas Boosts Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Teacher Retirement System of Texas raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 19.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,739 shares of the biopharmaceutical company’s stock after buying an additional 1,412 shares during the period. Teacher Retirement System of Texas’ holdings in Intra-Cellular Therapies were worth $357,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ITCI. Lord Abbett & CO. LLC purchased a new position in Intra-Cellular Therapies in the 1st quarter valued at about $72,004,000. Franklin Resources Inc. purchased a new position in Intra-Cellular Therapies in the 1st quarter valued at about $39,648,000. TimesSquare Capital Management LLC boosted its position in Intra-Cellular Therapies by 38.0% in the 1st quarter. TimesSquare Capital Management LLC now owns 1,227,280 shares of the biopharmaceutical company’s stock valued at $41,642,000 after buying an additional 338,080 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Intra-Cellular Therapies by 2,756.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 272,321 shares of the biopharmaceutical company’s stock valued at $11,114,000 after buying an additional 262,787 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Intra-Cellular Therapies by 4.4% in the 1st quarter. BlackRock Inc. now owns 6,158,133 shares of the biopharmaceutical company’s stock valued at $208,946,000 after buying an additional 259,565 shares during the last quarter. 81.80% of the stock is owned by institutional investors.

Shares of ITCI stock opened at $32.77 on Wednesday. Intra-Cellular Therapies, Inc. has a one year low of $22.92 and a one year high of $44.80. The company’s 50-day simple moving average is $34.15 and its 200-day simple moving average is $35.62. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -10.88 and a beta of 1.29.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Sunday, August 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.06). Intra-Cellular Therapies had a negative return on equity of 37.50% and a negative net margin of 425.79%. The company had revenue of $20.00 million for the quarter, compared to the consensus estimate of $19.04 million. The firm’s revenue for the quarter was up 952.6% compared to the same quarter last year. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -3.32 earnings per share for the current fiscal year.

Separately, Zacks Investment Research raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, September 9th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $39.33.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.

Read More: How to interpret the current ratio

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.